Sign In
Buy NVO
$47.64
+0.230 (+0.485%)
At Close: Jun 25, 2026
VIEW Lilly's obesity pill lags Novo's Wegovy injection in key trial
09:16am, Thursday, 07'th Aug 2025
Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight after 72 weeks in a late-stage study, less than previous trial results for Novo Nordisk's in
Investors who lost money on Novo Nordisk A/S(NVO) should contact The Gross Law Firm about pending Class Action - NVO
08:45am, Thursday, 07'th Aug 2025
NEW YORK , Aug. 7, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO). Shareholders who purchased shares of NVO during the class period
Novo Nordisk: The Market Has Lost Its Mind
08:04am, Thursday, 07'th Aug 2025
Novo Nordisk's shares have dropped significantly despite appealing Q2 results, creating an attractive entry point for long-term investors. The company continues to deliver double-digit revenue and pro
Novo Nordisk shares jump as Eli Lilly's weight-loss pill data disappoints
07:50am, Thursday, 07'th Aug 2025
Shares in Novo Nordisk rose 13.6% on Thursday after trial data from Eli Lilly's experimental weight-loss pill fell short of expectations, boosting investor confidence in the Danish drugmaker's market-
Novo Nordisk: More Pain On The Horizon
05:54am, Thursday, 07'th Aug 2025
Novo Nordisk faces slowing revenue growth, weak Q2 2025 results, and a more conservative outlook, signaling challenges ahead. Competition from Eli Lilly is intensifying, forcing Novo to increase marke
NEW YORK , Aug. 6, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO). Such investors ar
Hims & Hers: Still Growing After Breakup With Novo Nordisk
01:49pm, Wednesday, 06'th Aug 2025
Hims & Hers is positioned as a leading telehealth platform targeting millennial and Gen Z consumers with affordable, accessible healthcare solutions. The company's strong revenue growth, expanding pro
Novo Nordisk Q2 Earnings Beat, Sales Miss, GLP-1 Drugs Face US Hurdles
01:21pm, Wednesday, 06'th Aug 2025
NVO's Q2 earnings beat but revenues miss estimates as Wegovy and Ozempic face U.S. setbacks and rising competition.
Law Offices of Howard G. Smith Encourages Novo Nordisk A/S (NVO) Investors To Inquire About Securities Fraud Class Action
01:15pm, Wednesday, 06'th Aug 2025
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Novo Nordisk A/S (“Novo Nordisk” or the “
Law Offices of Frank R. Cruz Encourages Novo Nordisk A/S (NVO) Investors To Inquire About Securities Fraud Class Action
12:07pm, Wednesday, 06'th Aug 2025
LOS ANGELES--(BUSINESS WIRE)--Law Offices of Frank R. Cruz Encourages Novo Nordisk A/S (NVO) Investors To Inquire About Securities Fraud Class Action.
Novo Nordisk A/S (NVO) Q2 2025 Earnings Call Transcript
11:05am, Wednesday, 06'th Aug 2025
Novo Nordisk A/S (NVO) Q2 2025 Earnings Conference Call August 6, 2025 7:00 AM ET Company Participants David S. Moore - Executive VP of US Operations & Member of Management Board Jacob Martin Wiborg R
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S - NVO
10:00am, Wednesday, 06'th Aug 2025
NEW YORK , Aug. 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO). Such investors are advised to
Novo Nordisk Slumps As It Cautions 'Unsafe And Unlawful' Knockoffs Will Pressure Wegovy
09:16am, Wednesday, 06'th Aug 2025
Novo Nordisk stock slumped Wednesday after saying it expects compounded versions to undercut sales of its obesity drug, Wegovy.
Novo Nordisk: Is there life after slow death for slimmed down drug maker?
07:47am, Wednesday, 06'th Aug 2025
After a brutal 52% slide this year (not helped by a surprise profit warning last week), Novo Nordisk (NYSE:NVO) is struggling to regain its footing. Wednesday's second-quarter results confirmed the pi
Novo Norisk: The struggle is real and getting harder by the day
02:53am, Wednesday, 06'th Aug 2025
After last week's profit warning and leadership shake-up, Novo Nordisk's latest earnings update offered little new, though the company's growing struggle against rivals such as Eli Lilly and cheaper w
